AHR and breast carcinoma: Several recently published works, demonstrated that even in the absence of exogenous ligands, AHR is overexpressed and constitutively active in a variety of human and/or rodent tumors including breast cancer, lung adenocarcinoma, pancreatic and prostate cancer [12, 16, 17].